MetaADEDB 2.0 @ LMMD
Toremifene
(IWEQQRMGNVVKQW-OQKDUQJOSA-N)
Structure
SMILES
OC(=O)C(CC(=O)O)(CC(=O)O)O.ClCC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCN(C)C)/c1ccccc1
Molecular Formula:
C32H36ClNO8
Molecular Weight:
598.083
Log P:
4.9665
Hydrogen Bond Acceptor:
9
Hydrogen Bond Donor:
4
TPSA:
144.6
CAS Number(s):
89778-27-8
Synonym(s)
1.
Toremifene
2.
FC-1157a
3.
Fareston
4.
Toremifene Citrate
5.
Toremifene Citrate (1:1)
6.
Toremifene, (E)-Isomer
7.
Citrate, Toremifene
8.
FC 1157a
9.
FC1157a
External Link(s)
MeSHD017312
PubChem Compound3005572
ChEBI9636
CHEMBLCHEMBL1200675
KEGGdr:D00967
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Aspartate Aminotransferase IncreasedFAERS: 7US FAERS
2Alanine Aminotransferase IncreasedFAERS: 6US FAERS
3Endometrial hypertrophyFAERS: 6US FAERS
4Endometrial HyperplasiaFAERS: 5US FAERS
5Respiratory FailureFAERS: 5US FAERS
6Deep Vein ThrombosisFAERS: 3US FAERS
7FatigueFAERS: 3US FAERS
8Blood lactate dehydrogenase increasedFAERS: 2US FAERS
9DehydrationFAERS: 2US FAERS
10DizzinessFAERS: 2US FAERS
11Endometrial Stromal SarcomaFAERS: 2US FAERS
12Endometrial adenocarcinomaFAERS: 2US FAERS
13Endometrial thickeningFAERS: 2US FAERS
14No adverse eventFAERS: 2US FAERS
15PainFAERS: 2US FAERS
16PancreatitisFAERS: 2US FAERS
17Product use issueFAERS: 2US FAERS
18PruritusFAERS: 2US FAERS
19Pulmonary thrombosisFAERS: 2US FAERS
20ThrombophlebitisFAERS: 2US FAERS
21Uterine PolypFAERS: 2US FAERS
22White blood cell count decreasedFAERS: 2US FAERS
23jaundiceFAERS: 2US FAERS
24Abdominal discomfortFAERS: 1US FAERS
25AdenocarcinomaFAERS: 1US FAERS
26ArthralgiaFAERS: 1US FAERS
27AsphyxiaFAERS: 1US FAERS
28AstheniaFAERS: 1US FAERS
29Atrioventricular BlockFAERS: 1US FAERS
30Bacterial VaginosisFAERS: 1US FAERS
31Blood albumin decreasedFAERS: 1US FAERS
32Blood urea increasedFAERS: 1US FAERS
33BronchitisFAERS: 1US FAERS
34Burning sensationFAERS: 1US FAERS
35Cardiac ArrestFAERS: 1US FAERS
36Cervical polypFAERS: 1US FAERS
37CholelithiasisFAERS: 1US FAERS
38Diabetes MellitusFAERS: 1US FAERS
39DiscomfortFAERS: 1US FAERS
40Drug dispensing errorFAERS: 1US FAERS
41Drug dose omissionFAERS: 1US FAERS
42DyspepsiaFAERS: 1US FAERS
43Ear discomfortFAERS: 1US FAERS
44Endometrial cancer stage IIIFAERS: 1US FAERS
45Endometrial disorderFAERS: 1US FAERS
46Endometrial sarcomaFAERS: 1US FAERS
47EnterocolitisFAERS: 1US FAERS
48Feeling abnormalFAERS: 1US FAERS
49FlushingFAERS: 1US FAERS
50Gamma-Glutamyltransferase IncreasedFAERS: 1US FAERS
51Gastrooesophageal cancerFAERS: 1US FAERS
52HypokinesiaFAERS: 1US FAERS
53HypophagiaFAERS: 1US FAERS
54Inability to afford medicationFAERS: 1US FAERS
55Inappropriate schedule of product administrationFAERS: 1US FAERS
56Malignant neoplasm progressionFAERS: 1US FAERS
57MenorrhagiaFAERS: 1US FAERS
58Mood swingsFAERS: 1US FAERS
59Musculoskeletal stiffnessFAERS: 1US FAERS
60MyalgiaFAERS: 1US FAERS
61Myocardial InfarctionFAERS: 1US FAERS
62NauseaFAERS: 1US FAERS
63OverdoseFAERS: 1US FAERS
64PancytopeniaFAERS: 1US FAERS
65Pelvic PainFAERS: 1US FAERS
66Pelvic discomfortFAERS: 1US FAERS
67Psychiatric decompensationFAERS: 1US FAERS
68Pulmonary EmbolismFAERS: 1US FAERS
69Rectosigmoid cancerFAERS: 1US FAERS
70SwellingFAERS: 1US FAERS
71Tension HeadacheFAERS: 1US FAERS
72Urinary tract infectionFAERS: 1US FAERS
73Weight decreasedFAERS: 1US FAERS
74Wrong drug administeredFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.